Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline BRCA1 Mutation after Progression on FOLFIRINOX: Case Report and Literature Review

Metastatic pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. Until recently, cytotoxic chemotherapy was the only treatment option. Currently, there are subgroups of patients with PDAC either with somatic or germline mutations who are candidates for targeted agents. Germline mutations i...

Descripción completa

Detalles Bibliográficos
Autores principales: Pimenta, Jefferson Rios, Ueda, Serli Kiyomi Nakao, Peixoto, Renata D'Alpino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443654/
https://www.ncbi.nlm.nih.gov/pubmed/32884538
http://dx.doi.org/10.1159/000508533

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443654/
https://www.ncbi.nlm.nih.gov/pubmed/32884538
http://dx.doi.org/10.1159/000508533

Ejemplares similares